Effect of thermal therapy using hot water bottles on brain natriuretic peptide in chronic hemodialysis patients

Yoko Uchiyama-Tanaka

Yoko Clinic, Kitakyushu, Japan.

DOI: 10.4236/health.2013.52034                

Abstract

Introduction: The use of repeated thermal therapy for improving the symptoms of chronic heart failure (CHF) has been recently demonstrated. Usually, thermal therapy requires an infrared dry sauna. However, it is difficult for small clinics to acquire such an expensive and extensive system. The author assessed the efficacy of its substitution with hot water bottles. Moreover, there are no prior studies demonstrating the efficacy of thermal therapy in hemodialysis patients with chronic heart failure. Methods: The author evaluated plasma brain natriuretic peptide (BNP) levels in 98 hemodialysis patients in a clinic. A total of nine patients whose BNP levels were more than 500 pg/mL agreed to be enrolled in this study and received thermal therapy using hot water bottles. Results: Plasma BNP levels, a potential marker for CHF, tended to decrease (891 ± 448 pg/mL to 680 ± 339 pg/mL), but the difference was not significant (P = 0.0845). The oral temperature changed from 36.44℃± 0.45℃ to 37.04℃ ± 0.48℃ (+0.597℃, P < 0.0001). No side effects were experienced during the therapy. Moreover, most patients had an improvement in their symptoms and the ability to perform activities of daily living. Conclusion: Thermal therapy using hot water bottles is very safe and tends to reduce plasma BNP levels in hemodialysis patients with CHF.

Keywords

BNP; Brain Natriuretic Peptide; Chronic Heart Failure; Chronic Kidney Disease; Hemodialysis; Hot Water Bottle Thermal Therapy

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Parfery, P.S. and Foley, R.N. (1999) The clinical epidemiology of cardiac disease in chronic heart failure. Journal of the American Society of Nephrology, 10, 1606 1615.
[2]	Hamett, J.D., Foley, R.N., Kent, G.M., et al. (1995) Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney International, 47, 884-890. doi:10.1038/ki.1995.132
[3]	Ronco, C., Happio, M., House, A.A., et al. (2008) Cardio renal syndrome. Journal of the American College of Cardiology, 52, 1527-1539. doi:10.1016/j.jacc.2008.07.051
[4]	Kihara, T., Miyata, M., Fukudome, T., et al. (2009) Waon therapy improves the prognosis of patients with chronic heart failure. Journal of Cardiology, 53, 214-218. doi:10.1016/j.jjcc.2008.11.005
[5]	Miyata, M., Kihara, T., Kubozono, T., et al. (2008) Beneficial effects of Waon therapy on patients with chronic heart failure: Results of a prospective multicenter study. Journal of Cardiology, 52, 79-85. doi:10.1016/j.jjcc.2008.07.009
[6]	Kihara, T., Biro, S., Ikeda, Y., et al. (2004) Effects of repeated sauna treatment on ventricular arrhythmia inpatients with chronic heart failure. Circulation Journal, 68, 1146-1151. doi:10.1253/circj.68.1146
[7]	Wilkins, M.R., Redondo, J. and Brown, L.A. (1997) The natriuretic-peptide family. Lancet, 349, 1307-1310. doi:10.1016/S0140-6736(96)07424-7
[8]	Hunt, S.A., Baker, D.W., Chin, M.H., American College of Cardiology/American Heart Association, et al. (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/Ameri can Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Journal of American College of Cardiology, 38, 2101-2113. doi:10.1016/S0735-1097(01)01683-7
[9]	Tei, C., Prihara, K. and Fukudome, T. (2007) Remarkable efficacy of thermal therapy for Sjogren syndrome. Journal of Cardiology, 49, 217-219.
[10]	Biro, S., Masuda, A., Kihara, T., et al. (2003) Clinical implications of thermal therapy in lifestyle-related diseases. Experimental Biology and Medicine, 228, 1245 1249.
[11]	Madarame, H. and Kawashima, A. (2006) Use of hot water bottles can improve lymphocytopenia. Biomedical Research, 27, 45-48. doi:10.2220/biomedres.27.45
[12]	Toyabe, S., Iiai, T., Fukuda, M., et al. (1997) Identification of nicotinic acetylcholine receptors on lymphocytes in the periphery as well as thymus in mice. Immunology, 92, 201-205. doi:10.1046/j.1365-2567.1997.00323.x
[13]	Watanabe, M., Tomiyama-Miyaji, C., Kainuma, E., et al. (2008) Role of alpha-adrenergic stimulus in stress-induced modulation of body temperature, blood glucose and innate immunity. Immunology Letters, 115, 43-49. doi:10.1016/j.imlet.2007.09.010
[14]	Nishikimi, T., Futoo, Y., Tamano, K., et al. (2001) Plasma brain natriuretic peptide levels in chronic hemodialysis patients: Influence of coronary artery disease. American Journal of Kidney Disease, 37, 1201-1208. doi:10.1053/ajkd.2001.24523
[15]	Austin, W.J., Bhalla, V., Hernandez-Arce, I., et al. (2006) Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. American Journal of Clinical Pathology, 126, 506-512. doi:10.1309/M7AAXA0J1THMNCDF
[16]	McCullough, P.A., Duc, P., Omland, T., et al. (2003) Breathing not properly multinational study investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the breathing not properly multinational study. American Journal of Kidney Disease, 41, 571-579. doi:10.1053/ajkd.2003.50118
[17]	Naganuma, T., Sugimura, K., Wada, S., et al. (2002) The prognostic role of brain natriuretic peptides in hemodialysis patients. American Journal of Nephrology, 22, 437 444. doi:10.1159/000065272
[18]	Park, S., Cho, G.Y., Kim, S.G., et al. (2009) Brain natriuretic peptide levels have diagnostic and prognostic capability for cardio-renal syndrome type 4 in intensive care unit patients. Critical Care, 13, R70. doi:10.1186/cc7878
[19]	Akiba, T., Tachibana, K., Togashi, M., et al. (1995) Plasma human brain natriuretic peptide in chronic renal disease. Clinical Nephrology, 44, S61-S64.
[20]	Zoccali, C., Mallamaci, F., Benedetto, F.A., et al. (2001) Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. Journal of the American Society of Nephrology, 12, 1508-1515.
[21]	Takami, Y., Horio, T., Iwashima, Y., et al. (2004) Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. American Journal of Kidney Diseases, 44, 420-428.
[22]	Goto, T., Takase, H., Toriyama, T., et al. (2002) Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Ne phron, 92, 610-615. doi:10.1159/000064100
[23]	Gardin, J.M., Leifer, E.S., Fleg, J.L., HF-ACTION Investigators, et al. (2009) Relationship of doppler-echocar diographic left ventricular diastolic function to exercise performance in systolic heart failure: The HF-ACTION study. American Heart Journal, 58, S45-S52. doi:10.1016/j.ahj.2009.07.015
[24]	deFilippi, C.R., Fink, J.C., Nass, C.M., et al. (2005) N terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. American Journal of Kidney Diseases, 46, 35-44. doi:10.1053/j.ajkd.2005.04.007
[25]	Mark, P.B., Stewart, G.A., Gansevoort, R.T., et al. (2006) Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrology Dialysis Transplantation, 21, 402-410. doi:10.1093/ndt/gfi187